Patents by Inventor Joseph T. Witkowski

Joseph T. Witkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5487879
    Abstract: A stabilized, pressure-hydrated magnesium hydroxide slurry and a process for its production from burnt magnesite are described. According to an embodiment of the invention, a mixture comprising burnt natural magnesite and water is pressure hydrated to provide a pressure hydrated slurry. The pressure hydrated slurry is then deagglomerated. If desired, chloride ions and cationic polymer can be added to further stabilize the slurry.
    Type: Grant
    Filed: July 15, 1994
    Date of Patent: January 30, 1996
    Assignee: Martin Marietta Magnesia Specialities Inc.
    Inventors: Joseph T. Witkowski, David M. Smith, Mark T. Wajer
  • Patent number: 5470149
    Abstract: A sparger system for mixing a solid/liquid suspension in a cylindrical container comprises a sparger pipe which extends substantially parallel to the longitudinal axis of the container. The sparger pipe is separated from an inner wall of the container by a first distance and a first end portion of the sparger pipe extends through a side wall of the container. A first flange member is releasably coupled to the first end portion of the sparger pipe so that, when the first flange member is coupled to the first end portion of the sparger pipe, the first end of the sparger pipe is sealed. The flange member may be removed from the first end portion of the sparger so that pressurized liquid may be introduced directly into the sparger pipe to clean the sparger pipe and the container. A fluid passage is coupled to the sparger pipe and extends to an opening which is above a maximum level of liquid to be stored in the container.
    Type: Grant
    Filed: September 15, 1994
    Date of Patent: November 28, 1995
    Assignee: Martin Marietta Magnesia Specialties Inc.
    Inventors: Joseph T. Witkowski, Steve D. Raffensperger
  • Patent number: 4634689
    Abstract: Phosphinylalkanoyl imino acids useful in the treatment of hypertension are disclosed.
    Type: Grant
    Filed: October 31, 1985
    Date of Patent: January 6, 1987
    Assignee: Schering Corporation
    Inventors: Joseph T. Witkowski, Michael F. Czarniecki
  • Patent number: 4614743
    Abstract: The compound 4,7-dimethyl-2-(4-pyridinyl)-1,2,4-triazolo[1,5-a]pyrimidin-5(4H)-one and the pharmaceutically acceptable salts thereof are analgesic and anti-inflammatory agents. Methods for preparing and using the compound and salts are described.
    Type: Grant
    Filed: December 27, 1983
    Date of Patent: September 30, 1986
    Assignee: Schering Corporation
    Inventors: Richard E. Chipkin, Joseph T. Witkowski
  • Patent number: 4571402
    Abstract: Certain 2-(4'-pyridinyl)-thiazoles additionally substituted in either the 4- or 5- position are bronchodilating agents. Methods for their preparation and use are disclosed.
    Type: Grant
    Filed: May 9, 1983
    Date of Patent: February 18, 1986
    Assignee: Schering Corporation
    Inventors: Brooks R. Sunday, Joseph T. Witkowski
  • Patent number: 4528291
    Abstract: The pyridinyl-thiazole derivatives of the present invention exhibit good cardiotonic activity.
    Type: Grant
    Filed: June 22, 1982
    Date of Patent: July 9, 1985
    Assignee: Schering Corporation
    Inventors: Joseph T. Witkowski, Brooks R. Sunday
  • Patent number: 4497814
    Abstract: Disclosed are 2-(pyridinyl)-1,2,4-triazolo[1,5-a]pyrimidines and derivatives which are effective in increasing cardiac contractility. These compounds are useful in the treatment of congestive heart failure preferably by oral or parenteral administration.
    Type: Grant
    Filed: August 16, 1982
    Date of Patent: February 5, 1985
    Assignee: Schering Corporation
    Inventor: Joseph T. Witkowski
  • Patent number: 4431645
    Abstract: Compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are independently selected from hydrogen or lower alkyl; n is 1 or 0; A and B taken together with the carbons to which they are attached form an alkylene ring having six carbon atoms or A and B are hydrogen; and Z is ##STR2## The compounds are useful as hypertensive agents.
    Type: Grant
    Filed: March 8, 1982
    Date of Patent: February 14, 1984
    Assignee: Schering Corporation
    Inventors: Elizabeth M. Smith, Joseph T. Witkowski
  • Patent number: 4431644
    Abstract: Compounds of the formula ##STR1## and the pharmaceutically acceptable salts thereof, wherein R.sup.1, R.sup.2 and R.sup.4 are independently selected from hydrogen and lower alkyl; R.sup.3 is hydrogen, lower alkyl or amino lower alkyl; A and B taken together with the carbons to which they are attached form an alkylene ring having six carbon atoms or A and B are hydrogen; and Z is ##STR2## are disclosed. The compounds are useful as anti-hypertensive agents.
    Type: Grant
    Filed: March 8, 1982
    Date of Patent: February 14, 1984
    Assignee: Schering Corporation
    Inventors: Elizabeth M. Smith, Joseph T. Witkowski, Ronald J. Doll
  • Patent number: 4211771
    Abstract: The compound 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide is used to treat diseases in humans which are caused by viral infections.
    Type: Grant
    Filed: February 13, 1978
    Date of Patent: July 8, 1980
    Inventors: Joseph T. Witkowski, Roland K. Robins
  • Patent number: 4138547
    Abstract: 1-.beta.-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide is prepared by a process wherein a suitably substituted formimidic acid hydrazide is condensed with a blocked derivative of D-ribose and the intermediate is ring closed with a reagent which donates one carbon atom to yield a 3-substituted-1-(blocked .beta.-D-ribofuranosyl)-1,2,4-triazole. Treatment of this intermediate with ammonia and/or removal of the blocking group yields the product.
    Type: Grant
    Filed: December 22, 1977
    Date of Patent: February 6, 1979
    Assignee: ICN Pharmaceuticals, Inc.
    Inventors: Leon F. Christensen, Joseph T. Witkowski
  • Patent number: 3991078
    Abstract: Antiviral 1-(G)-1,2,4-triazole carboxamides, thiocarboxamides and carboxamidines wherein G is an acid labile hydrocarbon moiety, e.g., 1-(.alpha.-alkoxyalkyl), are prepared by, e.g., the acid-catalyzed addition reaction of appropriately substituted 1,2,4-triazole and an .alpha.,.beta.-unsaturated ether.
    Type: Grant
    Filed: March 18, 1974
    Date of Patent: November 9, 1976
    Assignee: ICN Pharmaceuticals, Inc.
    Inventors: Joseph T. Witkowski, Roland K. Robins
  • Patent number: 3984396
    Abstract: Phosphate and carboxylic acid esters of 1-(.beta.-D-ribofuranosyl)-1,2,4-triazoles are prepared by a variety of methods and their antiviral activity reported.
    Type: Grant
    Filed: March 18, 1974
    Date of Patent: October 5, 1976
    Assignee: ICN Pharmaceuticals, Inc.
    Inventors: Joseph T. Witkowski, Roland K. Robins
  • Patent number: 3976545
    Abstract: The use of 1,2,4-triazole-3-carboxamide and 1,2,4-triazole-3-thiocarboxamide and physiologically compatible salts thereof as antiviral agents is disclosed. A process for synthesizing 1-.beta.-D-ribofuranosyl-1,2,4-triazole-3-carboxamide is also disclosed.
    Type: Grant
    Filed: September 29, 1975
    Date of Patent: August 24, 1976
    Assignee: ICN Pharmaceuticals, Inc.
    Inventors: Joseph T. Witkowski, Roland K. Robins
  • Patent number: 3968103
    Abstract: Novel substituted 1,2,3-triazole nucleosides such as 4-R'-2-.beta.-D-ribofuranosyl-1,2,3-triazole wherein R' is a nitro, carboxylic acid ester, cyano, carboxamide or thiocarboxamide group are prepared by a procedure entailing fusion of an appropriately substituted 1,2,3-triazole with a tetra-0-acyl blocked ribofuranose. The resulting compounds exhibit significant antimicrobial activity in in vitro testing or are useful in preparing compounds which exhibit such activity.
    Type: Grant
    Filed: September 28, 1972
    Date of Patent: July 6, 1976
    Assignee: ICN Pharmaceuticals, Inc.
    Inventors: Roland K. Robins, Joseph T. Witkowski
  • Patent number: 3948885
    Abstract: A 5-hydroxy-1,2,3-triazole-4-carboxamide nucleoside, related to the C-nucleoside pyrazomycin, is facilely synthesized by condensation of acyl-blocked ribofuranose with trimethylsilylated 5-hydroxy-1,2,3-triazole-4-carboxamide or, alternatively, by cycloaddition of suitably blocked .beta.-D-ribofuranosyl azide and the anion of ethyl malonamate, and demonstrated to exhibit antiviral properties. The triazole precursor of the former route, as well as certain of its novel salts, are also disclosed as potential antiviral agents.
    Type: Grant
    Filed: March 19, 1973
    Date of Patent: April 6, 1976
    Assignee: ICN Pharmaceuticals, Inc.
    Inventors: Joseph T. Witkowski, Roland K. Robins, Frank A. Lehmkuhl
  • Patent number: RE29835
    Abstract: As antiviral agents and intermediates therefor, 3-substituted 1-(.beta.-D-glycosyl)-1,2,4-triazoles, O-acylated analogs thereof, and 5'- and 3',5'-cyclic phosphates of the triazole nucleosides, "glycosyl" being .[.a pentofuranosyl moiety, preferably one whose 2'-oxygen is trans to the triazole aglycon, e.g., xylofuranosyl,.]. ribofuranosyl, .[.2-0-methylribofuranosyl, etc.,.]. the triazole aglycon being 3-substituted with cyano, methylcarboxylate, carboxamidoxime, carboxamido-, thiocarboxamido, or carboxamidine. Preparation of these nucleosides is by silylation of the substituted triazole followed by glycosylation with the appropriate blocked glycosyl halide. Alternatively, acid-catalyzed fusion of the requisite 1,2,4-triazole with an O-acylated pentofuranose yields the nucleosides.
    Type: Grant
    Filed: March 28, 1977
    Date of Patent: November 14, 1978
    Assignee: ICN Pharmaceuticals
    Inventors: Joseph T. Witkowski, Roland K. Robins
  • Patent number: RE36369
    Abstract: A stabilized, pressure-hydrated magnesium hydroxide slurry and a process for its production from burnt magnesite are described. According to an embodiment of the invention, a mixture comprising burnt natural magnesite and water is pressure hydrated to provide a pressure hydrated slurry. The pressure hydrated slurry is then deagglomerated. If desired, chloride ions and cationic polymer can be added to further stabilize the slurry.
    Type: Grant
    Filed: November 19, 1996
    Date of Patent: November 2, 1999
    Assignee: Martin Marietta Magnesia Specialties, Inc.
    Inventors: Mark Thomas Wajer, Joseph T. Witkowski, David M. Smith